查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403426

迟发性治疗药物到2030年的全球市场预测：依产品类型、疾病类型、给药途径、配销通路和地区进行分析

Tardive Dyskinesia Therapeutics Market Forecasts to 2030 - Global Analysis By Product Type, Disease Type, Route Of Administration, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球迟发性药物市场规模将达到 25 亿美元，预计 2030 年将达到 54 亿美元，预测期内复合年增长率为 11.1%。

药物引起的运动疾病称为迟发性(TD)，会导致舌头、脸部、躯干和四肢不受控制地运动。迟发性是长期使用某些精神药物（如抗精神病药物）的副作用。儘管有时也会影响其他患者，但这种疾病最常见于长期服用抗精神病药物的精神分裂症、分裂情感性疾患和躁郁症患者。

根据 John Wiley &Sons, Inc. 于 2022 年 8 月发表的一篇论文，在欧洲接受抗精神病药物治疗的精神病患者中，迟发性的盛行率为 23.3%。

迟发性盛行率上升

提高认识可能有助于早期发现和治疗，减轻症状的严重。研究的进步将导致更专业的药物和治疗方法的开发，为受影响的人提供更个性化的护理。此外，提高意识将鼓励为进一步研究提供资金筹措，激发创造力，发现治疗和预防迟发性的新方法，并最终减少受这种疾病影响的人数，提高人们的生活品质。

复杂的管理

迟发性的治疗通常涉及多种策略的组合，包括改变目前的治疗方案或添加新的治疗方案。这种复杂性可能会使治疗变得困难，尤其是在兼顾控制原始药物所治疗的潜在疾病的需要时。用于控制它的治疗方法可能会产生轻微到严重的副作用，可能需要密切监测和管理。

改善识别和诊断

早期发现可以及时治疗，减缓病程并改善患者的治疗效果。更多知识使医疗保健专业人员能够积极监测患者，从而更容易快速改变处方时间表或使用其他治疗方法来控制症状。此外，增加知识有助于患者教育和支持、减少耻辱并促进富有同情心的医疗保健方法。这样的综合策略最终将改善人们的生活品质并促进市场扩张。

製药公司研发投入限制

治疗罕见疾病药物研发的主要挑战之一是能够参与临床试验的患者数量较少。只有几百、几千名罕见疾病患者有资格参加临床试验。罕见疾病患者数量非常少。此外，研究费用昂贵且投资回报不明，这可能导致製药公司不愿为其提供资金。

新冠肺炎 (COVID-19) 影响：

这场大流行扰乱了全球医疗保健服务，影响了常规检查、专家咨询以及面对面治疗的可用性。结果，许多迟发性患者的治疗被推迟或中断。 COVID-19 影响了正在进行的与迟发性相关的临床试验和研究的进展。由于探视限製或入组挑战，一些临床试验可能会被推迟或修改。

预计在预测期内，丁苯那嗪部分将是最大的

预计Deutetrabenazine细分市场在预测期内将是最大的细分市场。氘替代延长了半衰期，提高了疗效和安全性，减少了与给药相关的副作用，并提高了患者的医嘱遵从性。这种化合物有望抑制与迟发性相关的不自主运动，从而提供更一致且更易于管理的治疗方法。

迟发性肌张力不全症地区预计在预测期内复合年增长率最高

迟发性肌张力不全症领域预计在预测期内复合年增长率最高。迟发性肌张力不全症是迟发性的一种亚型，具体涉及持续的肌肉收缩，导致重复的扭转运动和异常姿势。调整或停用引发迟发性肌张力不全症的药物可能会改善或消除症状。然而，这种情况必须由医疗专业人员仔细处理，平衡药物的益处与精神状态恶化的风险。

比最大的地区

预计北美在预测期内将占据最大的市场占有率。多家製药公司正在投资开发专门用于症状管理的药物。这些治疗旨在透过减轻与疾病相关的不自主运动来改善受影响个体的生活品质。随着治疗方法选择的进步以及医疗保健提供者对这些治疗方法的接受程度不断提高，市场正在呈现成长。

复合年增长率最高的地区：

由于医疗保健意识的提高、诊断技术的改进和高龄化，预计亚太地区在预测期内将保持最高的复合年增长率。製药公司正在努力开发针对症状的新治疗方法和药物，以解决该领域未满足的医疗需求。国内和全球製药公司之间的合作以及诊断和治疗技术的进步也有助于该地区的市场扩张。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球迟发性治疗市场：依产品类型

  • 缬苯那嗪
  • Tetrabenazine
  • 氯硝西泮
  • 维生素E
  • 苯二氮平类
  • Ondansetron
  • Tetrabenazine
  • 赖血平
  • 普萘洛尔
  • 多巴胺消耗剂

第六章全球迟发性治疗市场：依疾病类型

  • 迟发性不能
  • 迟发性口腔面部运动障碍
  • 迟发性肌张力不全症
  • 迟发性眼睑痉挛
  • 迟发性抽动

第七章全球迟发性治疗市场：依给药途径

  • 口服
  • 注射

第八章全球迟发性治疗药物市场：按配销通路

  • 医院药房
  • 药局和零售药局
  • 线上药房
  • 其他配销通路

第九章全球迟发性治疗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司简介

  • Mitsubishi Tanabe Pharma Corporation
  • Luye Pharma Group
  • Teva Pharmaceutical Industries Ltd.
  • Neurocrine Biosciences, Inc.
  • SOM BIOTECH
  • Sun Pharmaceutical Industries Ltd
  • AbbVie Inc
  • Sanis
  • SteriMax Inc.
  • Adamas Pharmaceuticals, Inc
  • Reddys Laboratories Ltd
  • Mylan NV
  • Bausch Health
  • Johnson & Johnson Services
  • Lupin Pharmaceuticals Inc
  • Novartis AG
  • Baxter
  • Amgen Inc
  • Pfizer Inc
  • Medicure Inc
Product Code: SMRC24651

According to Stratistics MRC, the Global Tardive Dyskinesia Therapeutics Market is accounted for $2.5 billion in 2023 and is expected to reach $5.4 billion by 2030 growing at a CAGR of 11.1% during the forecast period. A drug-induced movement condition called tardive dyskinesia (TD) results in uncontrollably moving the tongue, face, torso, and limbs. It is a side effect brought on by extended use of specific psychiatric drug classes, such antipsychotics. Although they sometimes afflict other patients as well, the illness is most frequent among those who have been taken long-term antipsychotic drugs for schizophrenia, schizoaffective disorder, or bipolar disorder.

According to an article published by John Wiley & Sons, Inc., in August 2022, the prevalence of tardive dyskinesia in Europe is 23.3% amongst psychiatric patients receiving treatment with antipsychotics.

Market Dynamics:

Driver:

Rising prevalence of tardive dyskinesia

Increased consciousness encourages early identification and action, which may lessen the severity of symptoms. Research progresses lead to the creation of more specialized drugs and therapies, providing impacted people with more individualized care. Furthermore, greater awareness encourages financing for additional research, which spurs creativity and reveals fresh approaches to tardive dyskinesia therapy and prevention, eventually enhancing the quality of life for individuals affected by the disorder.

Restraint:

Complexity in management

The management of tardive dyskinesia frequently entails a mix of strategies, such as changing current prescriptions or adding new ones. This intricacy can make treatment difficult, particularly when juggling the requirement to manage the underlying condition for which the original medication was prescribed. Therapeutic options for management have a range of side effects, from mild to severe, which may require close monitoring and management.

Opportunity:

Increased awareness and diagnosis

Early detection enables timely management, which may slow its course and enhance patient outcomes. Increased knowledge encourages healthcare professionals to monitor patients proactively, which makes it easier to control symptoms by promptly changing prescription schedules or using other therapies. Moreover, better knowledge promotes patient education and support, lessens stigma, and encourages a more compassionate approach to healthcare. This all-encompassing strategy eventually improves people's quality of life, which fuels market expansion.

Threat:

Limited R&D investment by pharmaceutical companies

One of the major challenges of rare disease drugs in terms of research and development is the small patient population available for clinical trials. Only a few hundred or few thousand patients with rare diseases are accessible for clinical trials. Rare diseases afflict a tiny population. Furthermore, because research may be expensive and have hazy returns on investment, pharmaceutical corporations could be reluctant to fund it.

COVID-19 Impact:

The pandemic caused disruptions in healthcare services globally, affecting regular check-ups, access to specialists, and availability of in-person treatments. This led to delays or interruptions in treatment for many individuals with tardive dyskinesia. COVID-19 impacted the progress of ongoing clinical trials and research studies related to tardive dyskinesia. Some trials might have been delayed or modified due to restrictions on in-person visits and enrollment challenges.

The deutetrabenazine segment is expected to be the largest during the forecast period

The deutetrabenazine segment is expected to be the largest during the forecast period. Its deuterium substitution enhances its efficacy and safety profile by prolonging its half-life, leading to fewer dose-related side effects and improved patient adherence. This compound demonstrates potential in reducing involuntary movements associated with Tardive Dyskinesia while offering a more consistent and manageable treatment approach.

The tardive dystonia segment is expected to have the highest CAGR during the forecast period

The tardive dystonia segment is expected to have the highest CAGR during the forecast period. Tardive dystonia, a subtype of tardive dyskinesia, specifically involves sustained muscle contractions causing repetitive, twisting movements or abnormal postures. Sometimes, adjusting or discontinuing the medications that trigger tardive dystonia can lead to improvement or resolution of symptoms. However, this must be carefully managed by a healthcare professional to balance the benefits of the medication with the risk of worsening psychiatric conditions.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. Several pharmaceutical companies have been investing in developing medications specifically targeted to manage symptoms. These treatments aim to alleviate the involuntary movements associated with the condition, thereby improving the quality of life for affected individuals. The market has shown growth in terms of advancements in therapeutic options and the growing acceptance of these treatments among healthcare providers.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to rising healthcare awareness, improving diagnostic techniques, and an aging population. Pharmaceutical companies were working on developing new treatments and medications targeting symptoms, aiming to address the unmet medical needs in this area. Collaborations between local and global pharmaceutical companies, as well as advancements in technology for diagnosis and treatment, were also contributing to the expansion of the market in the region.

Key players in the market:

Some of the key players in Tardive Dyskinesia Therapeutics market include Mitsubishi Tanabe Pharma Corporation, Luye Pharma Group, Teva Pharmaceutical Industries Ltd., Neurocrine Biosciences, Inc., SOM BIOTECH, Sun Pharmaceutical Industries Ltd, AbbVie Inc , Sanis, SteriMax Inc., Adamas Pharmaceuticals, Inc , Reddys Laboratories Ltd, Mylan N.V., Bausch Health, Johnson & Johnson Services, Lupin Pharmaceuticals Inc, Novartis AG, Baxter, Amgen Inc, Pfizer Inc and Medicure Inc.

Key Developments:

In February 2023, Teva Pharmaceuticals announced the print publication of the IMPACT-TD Scale, an easy-to-use, standardized and clinician-rated assessment. The scale, developed by a consensus panel, will assist healthcare providers in determining the impact of tardive dyskinesia (TD) on different aspects of a patient's daily functioning.

In December 2021, Mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical K.K. have entered into a co-promotion agreement for MT-5199, a vesicular monoamine transporter type 2 (VMAT2) inhibitor, which is intended for use as tardive dyskinesia therapeutics in Japan.

Product Types Covered:

  • Valbenazine
  • Deutetrabenazine
  • Clonazepam
  • Vitamin E
  • Benzodiazepines
  • Ondansetron
  • Tetrabenazine
  • Reserpine
  • Propranolol
  • Dopamine-Depleting Agents

Disease Types Covered:

  • Tardive akathisia
  • Tardive Orofacial Dyskinesia
  • Tardive Dystonia
  • Tardive Blepharospasm
  • Tardive Tics

Route Of Administration Covered:

  • Oral
  • Injectable

Distribution Channels Covered:

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Tardive Dyskinesia Therapeutics Market, By Product Type

  • 5.1 Introduction
  • 5.2 Valbenazine
  • 5.3 Deutetrabenazine
  • 5.4 Clonazepam
  • 5.5 Vitamin E
  • 5.6 Benzodiazepines
  • 5.7 Ondansetron
  • 5.8 Tetrabenazine
  • 5.9 Reserpine
  • 5.10 Propranolol
  • 5.11 Dopamine-Depleting Agents

6 Global Tardive Dyskinesia Therapeutics Market, By Disease Type

  • 6.1 Introduction
  • 6.2 Tardive akathisia
  • 6.3 Tardive Orofacial Dyskinesia
  • 6.4 Tardive Dystonia
  • 6.5 Tardive Blepharospasm
  • 6.6 Tardive Tics

7 Global Tardive Dyskinesia Therapeutics Market, By Route Of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Injectable

8 Global Tardive Dyskinesia Therapeutics Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Drug Stores & Retail Pharmacies
  • 8.4 Online Pharmacies
  • 8.5 Other Distribution Channels

9 Global Tardive Dyskinesia Therapeutics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Mitsubishi Tanabe Pharma Corporation
  • 11.2 Luye Pharma Group
  • 11.3 Teva Pharmaceutical Industries Ltd.
  • 11.4 Neurocrine Biosciences, Inc.
  • 11.5 SOM BIOTECH
  • 11.6 Sun Pharmaceutical Industries Ltd
  • 11.7 AbbVie Inc
  • 11.8 Sanis
  • 11.9 SteriMax Inc.
  • 11.10 Adamas Pharmaceuticals, Inc
  • 11.11 Reddys Laboratories Ltd
  • 11.12 Mylan N.V.
  • 11.13 Bausch Health
  • 11.14 Johnson & Johnson Services
  • 11.15 Lupin Pharmaceuticals Inc
  • 11.16 Novartis AG
  • 11.17 Baxter
  • 11.18 Amgen Inc
  • 11.19 Pfizer Inc
  • 11.20 Medicure Inc

List of Tables

  • Table 1 Global Tardive Dyskinesia Therapeutics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Tardive Dyskinesia Therapeutics Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 3 Global Tardive Dyskinesia Therapeutics Market Outlook, By Valbenazine (2021-2030) ($MN)
  • Table 4 Global Tardive Dyskinesia Therapeutics Market Outlook, By Deutetrabenazine (2021-2030) ($MN)
  • Table 5 Global Tardive Dyskinesia Therapeutics Market Outlook, By Clonazepam (2021-2030) ($MN)
  • Table 6 Global Tardive Dyskinesia Therapeutics Market Outlook, By Vitamin E (2021-2030) ($MN)
  • Table 7 Global Tardive Dyskinesia Therapeutics Market Outlook, By Benzodiazepines (2021-2030) ($MN)
  • Table 8 Global Tardive Dyskinesia Therapeutics Market Outlook, By Ondansetron (2021-2030) ($MN)
  • Table 9 Global Tardive Dyskinesia Therapeutics Market Outlook, By Tetrabenazine (2021-2030) ($MN)
  • Table 10 Global Tardive Dyskinesia Therapeutics Market Outlook, By Reserpine (2021-2030) ($MN)
  • Table 11 Global Tardive Dyskinesia Therapeutics Market Outlook, By Propranolol (2021-2030) ($MN)
  • Table 12 Global Tardive Dyskinesia Therapeutics Market Outlook, By Dopamine-Depleting Agents (2021-2030) ($MN)
  • Table 13 Global Tardive Dyskinesia Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 14 Global Tardive Dyskinesia Therapeutics Market Outlook, By Tardive akathisia (2021-2030) ($MN)
  • Table 15 Global Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Orofacial Dyskinesia (2021-2030) ($MN)
  • Table 16 Global Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Dystonia (2021-2030) ($MN)
  • Table 17 Global Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Blepharospasm (2021-2030) ($MN)
  • Table 18 Global Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Tics (2021-2030) ($MN)
  • Table 19 Global Tardive Dyskinesia Therapeutics Market Outlook, By Route Of Administration (2021-2030) ($MN)
  • Table 20 Global Tardive Dyskinesia Therapeutics Market Outlook, By Oral (2021-2030) ($MN)
  • Table 21 Global Tardive Dyskinesia Therapeutics Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 22 Global Tardive Dyskinesia Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 23 Global Tardive Dyskinesia Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 24 Global Tardive Dyskinesia Therapeutics Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
  • Table 25 Global Tardive Dyskinesia Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 26 Global Tardive Dyskinesia Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 27 North America Tardive Dyskinesia Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 28 North America Tardive Dyskinesia Therapeutics Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 29 North America Tardive Dyskinesia Therapeutics Market Outlook, By Valbenazine (2021-2030) ($MN)
  • Table 30 North America Tardive Dyskinesia Therapeutics Market Outlook, By Deutetrabenazine (2021-2030) ($MN)
  • Table 31 North America Tardive Dyskinesia Therapeutics Market Outlook, By Clonazepam (2021-2030) ($MN)
  • Table 32 North America Tardive Dyskinesia Therapeutics Market Outlook, By Vitamin E (2021-2030) ($MN)
  • Table 33 North America Tardive Dyskinesia Therapeutics Market Outlook, By Benzodiazepines (2021-2030) ($MN)
  • Table 34 North America Tardive Dyskinesia Therapeutics Market Outlook, By Ondansetron (2021-2030) ($MN)
  • Table 35 North America Tardive Dyskinesia Therapeutics Market Outlook, By Tetrabenazine (2021-2030) ($MN)
  • Table 36 North America Tardive Dyskinesia Therapeutics Market Outlook, By Reserpine (2021-2030) ($MN)
  • Table 37 North America Tardive Dyskinesia Therapeutics Market Outlook, By Propranolol (2021-2030) ($MN)
  • Table 38 North America Tardive Dyskinesia Therapeutics Market Outlook, By Dopamine-Depleting Agents (2021-2030) ($MN)
  • Table 39 North America Tardive Dyskinesia Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 40 North America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive akathisia (2021-2030) ($MN)
  • Table 41 North America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Orofacial Dyskinesia (2021-2030) ($MN)
  • Table 42 North America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Dystonia (2021-2030) ($MN)
  • Table 43 North America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Blepharospasm (2021-2030) ($MN)
  • Table 44 North America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Tics (2021-2030) ($MN)
  • Table 45 North America Tardive Dyskinesia Therapeutics Market Outlook, By Route Of Administration (2021-2030) ($MN)
  • Table 46 North America Tardive Dyskinesia Therapeutics Market Outlook, By Oral (2021-2030) ($MN)
  • Table 47 North America Tardive Dyskinesia Therapeutics Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 48 North America Tardive Dyskinesia Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 49 North America Tardive Dyskinesia Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 50 North America Tardive Dyskinesia Therapeutics Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
  • Table 51 North America Tardive Dyskinesia Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 52 North America Tardive Dyskinesia Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 53 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 54 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 55 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Valbenazine (2021-2030) ($MN)
  • Table 56 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Deutetrabenazine (2021-2030) ($MN)
  • Table 57 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Clonazepam (2021-2030) ($MN)
  • Table 58 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Vitamin E (2021-2030) ($MN)
  • Table 59 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Benzodiazepines (2021-2030) ($MN)
  • Table 60 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Ondansetron (2021-2030) ($MN)
  • Table 61 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Tetrabenazine (2021-2030) ($MN)
  • Table 62 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Reserpine (2021-2030) ($MN)
  • Table 63 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Propranolol (2021-2030) ($MN)
  • Table 64 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Dopamine-Depleting Agents (2021-2030) ($MN)
  • Table 65 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 66 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Tardive akathisia (2021-2030) ($MN)
  • Table 67 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Orofacial Dyskinesia (2021-2030) ($MN)
  • Table 68 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Dystonia (2021-2030) ($MN)
  • Table 69 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Blepharospasm (2021-2030) ($MN)
  • Table 70 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Tics (2021-2030) ($MN)
  • Table 71 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Route Of Administration (2021-2030) ($MN)
  • Table 72 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Oral (2021-2030) ($MN)
  • Table 73 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 74 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 75 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 76 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
  • Table 77 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 78 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 79 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 80 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 81 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Valbenazine (2021-2030) ($MN)
  • Table 82 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Deutetrabenazine (2021-2030) ($MN)
  • Table 83 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Clonazepam (2021-2030) ($MN)
  • Table 84 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Vitamin E (2021-2030) ($MN)
  • Table 85 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Benzodiazepines (2021-2030) ($MN)
  • Table 86 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Ondansetron (2021-2030) ($MN)
  • Table 87 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Tetrabenazine (2021-2030) ($MN)
  • Table 88 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Reserpine (2021-2030) ($MN)
  • Table 89 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Propranolol (2021-2030) ($MN)
  • Table 90 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Dopamine-Depleting Agents (2021-2030) ($MN)
  • Table 91 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 92 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Tardive akathisia (2021-2030) ($MN)
  • Table 93 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Orofacial Dyskinesia (2021-2030) ($MN)
  • Table 94 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Dystonia (2021-2030) ($MN)
  • Table 95 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Blepharospasm (2021-2030) ($MN)
  • Table 96 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Tics (2021-2030) ($MN)
  • Table 97 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Route Of Administration (2021-2030) ($MN)
  • Table 98 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Oral (2021-2030) ($MN)
  • Table 99 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 100 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 101 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 102 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
  • Table 103 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 104 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 105 South America Tardive Dyskinesia Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 106 South America Tardive Dyskinesia Therapeutics Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 107 South America Tardive Dyskinesia Therapeutics Market Outlook, By Valbenazine (2021-2030) ($MN)
  • Table 108 South America Tardive Dyskinesia Therapeutics Market Outlook, By Deutetrabenazine (2021-2030) ($MN)
  • Table 109 South America Tardive Dyskinesia Therapeutics Market Outlook, By Clonazepam (2021-2030) ($MN)
  • Table 110 South America Tardive Dyskinesia Therapeutics Market Outlook, By Vitamin E (2021-2030) ($MN)
  • Table 111 South America Tardive Dyskinesia Therapeutics Market Outlook, By Benzodiazepines (2021-2030) ($MN)
  • Table 112 South America Tardive Dyskinesia Therapeutics Market Outlook, By Ondansetron (2021-2030) ($MN)
  • Table 113 South America Tardive Dyskinesia Therapeutics Market Outlook, By Tetrabenazine (2021-2030) ($MN)
  • Table 114 South America Tardive Dyskinesia Therapeutics Market Outlook, By Reserpine (2021-2030) ($MN)
  • Table 115 South America Tardive Dyskinesia Therapeutics Market Outlook, By Propranolol (2021-2030) ($MN)
  • Table 116 South America Tardive Dyskinesia Therapeutics Market Outlook, By Dopamine-Depleting Agents (2021-2030) ($MN)
  • Table 117 South America Tardive Dyskinesia Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 118 South America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive akathisia (2021-2030) ($MN)
  • Table 119 South America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Orofacial Dyskinesia (2021-2030) ($MN)
  • Table 120 South America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Dystonia (2021-2030) ($MN)
  • Table 121 South America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Blepharospasm (2021-2030) ($MN)
  • Table 122 South America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Tics (2021-2030) ($MN)
  • Table 123 South America Tardive Dyskinesia Therapeutics Market Outlook, By Route Of Administration (2021-2030) ($MN)
  • Table 124 South America Tardive Dyskinesia Therapeutics Market Outlook, By Oral (2021-2030) ($MN)
  • Table 125 South America Tardive Dyskinesia Therapeutics Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 126 South America Tardive Dyskinesia Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 127 South America Tardive Dyskinesia Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 128 South America Tardive Dyskinesia Therapeutics Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
  • Table 129 South America Tardive Dyskinesia Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 130 South America Tardive Dyskinesia Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 131 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 132 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 133 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Valbenazine (2021-2030) ($MN)
  • Table 134 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Deutetrabenazine (2021-2030) ($MN)
  • Table 135 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Clonazepam (2021-2030) ($MN)
  • Table 136 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Vitamin E (2021-2030) ($MN)
  • Table 137 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Benzodiazepines (2021-2030) ($MN)
  • Table 138 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Ondansetron (2021-2030) ($MN)
  • Table 139 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Tetrabenazine (2021-2030) ($MN)
  • Table 140 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Reserpine (2021-2030) ($MN)
  • Table 141 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Propranolol (2021-2030) ($MN)
  • Table 142 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Dopamine-Depleting Agents (2021-2030) ($MN)
  • Table 143 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 144 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Tardive akathisia (2021-2030) ($MN)
  • Table 145 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Orofacial Dyskinesia (2021-2030) ($MN)
  • Table 146 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Dystonia (2021-2030) ($MN)
  • Table 147 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Blepharospasm (2021-2030) ($MN)
  • Table 148 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Tics (2021-2030) ($MN)
  • Table 149 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Route Of Administration (2021-2030) ($MN)
  • Table 150 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Oral (2021-2030) ($MN)
  • Table 151 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 152 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 153 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 154 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
  • Table 155 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 156 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)